Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, placebo-controlled, cross-over trial comparing the the effects of
approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on
several parameters of reverse cholesterol transport (RCT) in men and post-menopausal women
diagnosed with hypercholesterolemia. The primary hypothesis is that the ezetimibe treatment
will increase the excretion of endogenous (plasma-derived) cholesterol as fecal sterols, with
secondary hypotheses that there will be a significant increase in de novo cholesterol
synthesis, treatment will increase cholesterol efflux from tissues into the bloodstream, and
increase global RCT.